NCT02226510View on ClinicalTrials.gov

MetfoRmin and Its Effects on Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

December 31, 2017

Conditions
Left Ventricular HypertrophyInsulin ResistanceCoronary Artery DiseasePreDiabetes
Interventions
DRUG

Metformin XL

In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day . They will continue on Metformin XL 500mg x2/day for 2 weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day.

DRUG

Placebo

Placebo capsules (with an identical appearance to the active drug) containing only microcrystalline cellulose PhEur will be administered.

Trial Locations (1)

DD1 9SY

Ninewells Hospital & Medical School, Dundee

All Listed Sponsors
lead

University of Dundee

OTHER

NCT02226510 - MetfoRmin and Its Effects on Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease | Biotech Hunter | Biotech Hunter